Respiratory News and Research

RSS

Short chain fatty acids have potential therapeutic applications against COVID-19, study suggests

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is highly transmissible, with nasal passages being the target of original infection.

15 Jul 2021

Rapid COVID-19 antibody detection with time‐resolved fluorescence immunoassay

A new study published in the journal Biotechnology and Applied Biochemistry deals with the development of a time-resolved fluorescence immunoassay (TRFIA) for the detection of total COVID-19 antibodies in humans.

15 Jul 2021

Should we be concerned about the SARS-CoV-2 Lambda variant?

As the coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wreaks havoc across the globe, the efficacy of available vaccines is being threatened by emerging variants.

15 Jul 2021

Could new strains of COVID evolve in farm animals or pets?

It appears no one is safe from severe acute respiratory coronavirus 2 (SARS-CoV-2). Given that SARS-CoV-2 likely developed in bats and later transmitted to humans in Wuhan, China, there has been concern over animals infecting humans. But more evidence has shown that humans are more likely to infect animals — from hamsters, gorillas to the domestic cat.

14 Jul 2021

A pencil graphite biosensor that detects SARS-CoV-2

In a new study, scientists discuss the development of a rapid COVID-19 diagnostic tool known as the Low-cost Electrochemical Advanced Diagnostic (LEAD).

14 Jul 2021

New online educational program on shared decision making in lung cancer screening

The American College of Chest Physicians and Thomas Jefferson University are launching a free online educational program titled "Shared Decision Making in Lung Cancer Screening" to assist healthcare workers with identifying eligible patients for lung cancer screening and helping patients make a well-informed decision about whether to be screened.

14 Jul 2021

Full intensity heparin has value in treating hospitalized COVID-19 patients

Results from the RAPID clinical trial suggest heparin may lower the risk of death from moderate COVID-19 infection by 78%. Heparin also significantly increased the number of days patients went without ventilation or requiring organ support.

14 Jul 2021

“Herd immunity” not responsible for Sweden’s control of COVID-19, say researchers

Researchers in Sweden have challenged the interpretation that variable non-pharmaceutical interventions (NPIs) and “herd immunity” protection are responsible for the rise and fall of coronavirus disease 2019 (COVID-19) epidemic waves in hard-hit locations where authorities have not enforced strict NPIs.

14 Jul 2021

Diagnosis and management of COVID-19 in clinical settings

The coronavirus disease 2019 (COVID-19) outbreak has spread throughout the globe and much time has passed since it was declared as a pandemic by the World Health Organization (WHO).

14 Jul 2021

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers in Italy have demonstrated the efficacy of using modified outer membrane vesicles (OMVs) as a vaccine to protect against coronavirus disease 2019 (COVID-19) in an animal model.

14 Jul 2021

Could corticosteroids increase mortality in COVID-19 patients without high oxygen supplementation?

A new paper focuses on the role of corticosteroids, in particular, as these were widely used among patients on intensive respiratory support (IRS).

14 Jul 2021

Nanopore technology allows point-of-care SARS-CoV-2 genomic sequencing

As the SARS-CoV-2 continues to spread worldwide and cause disease and death on a devastating scale, genomic sequencing has become a primary method of keeping track of emerging variants and new outbreaks. A new medRxiv* preprint explores the role of nanopore sequencing in this effort.

14 Jul 2021

Vaccine hesitancy among young adults may stall efforts to achieve herd immunity

Vaccine skepticism among young adults may stall efforts to achieve herd immunity - a threshold in which approximately 80 percent of a population is vaccinated against the coronavirus.

14 Jul 2021

COVID-19 vaccine booster strategy against Delta variant evidence of growing inequity, says WHO

Could the COVID-19 vaccine booster dose strategy being planned in wealthyy nations underscore issues of health inequality?

14 Jul 2021

Is niclosamide a potential SARS-CoV-2 antiviral inhibitor?

Niclosamide is an antihelminthic drug, historically used to treat tapeworm infestations, though has been investigated and repurposed for use against SARS-CoV-2. In a new study recently uploaded to the preprint server bioRxiv* by Garrett et al. (July 12, 2021), the drug demonstrates the ability to reorganize the lipid profile of SARS-CoV-2 infected Vero E6 cells, thereby limiting virus replication.

14 Jul 2021

Researchers examine efficacy of CT-P59 monoclonal antibody against SARS-CoV-2 Brazil variant

The therapeutic monoclonal antibody CT-P59 binds to the RBD of SARS-CoV-2, the site of these three major mutations, which may therefore reduce the potency of this antibody against the P.1 lineage. In a new study, the neutralizing potency of this monoclonal antibody towards both wildtype and P.1 SARS-CoV-2 is investigated. The researchers found that the ability to bind with the virus is impeded by the mutations, resulting in reduced potency in vitro.

14 Jul 2021

SARS-CoV-2 variants show distinct humoral response and transcriptional profiles in hamster model

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel, highly infectious respiratory virus, and the causative agent of coronavirus disease 2019 (COVID-19) pandemic. SARS-CoV-2, which first originated in Wuhan, in Hubei province of China, is a member of the Coronavirdae family and has a large, non-segmented RNA genome.

14 Jul 2021

High individual-level variability in SARS-CoV-2 shedding may explain superspreading

Researchers in the United States have provided a high-resolution description of the viral dynamics involved in acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Jul 2021

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Researchers in the United States have demonstrated that the viral spike protein used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells adopts an open conformation exposing novel epitopes that could serve as targets for therapeutic strategies to protect against coronavirus disease 2019 (COVID-19).

14 Jul 2021

Israeli study of breakthrough infections following full BNT-Pfizer vaccination, 40% immunocompromised

Severe forms of coronavirus disease (COVID-19) linked to high mortality rates might arise in a minority of fully-vaccinated individuals with many co-occurring medical conditions, finds a recent study by Israeli researchers published in the journal Clinical Microbiology and Infection.

13 Jul 2021

Respiratory News and Research

Short chain fatty acids have potential therapeutic applications against COVID-19, study suggests

Rapid COVID-19 antibody detection with time‐resolved fluorescence immunoassay

Should we be concerned about the SARS-CoV-2 Lambda variant?

Could new strains of COVID evolve in farm animals or pets?

A pencil graphite biosensor that detects SARS-CoV-2

New online educational program on shared decision making in lung cancer screening

Full intensity heparin has value in treating hospitalized COVID-19 patients

“Herd immunity” not responsible for Sweden’s control of COVID-19, say researchers

Diagnosis and management of COVID-19 in clinical settings

New OMV-based COVID-19 vaccine candidate proves effective in mice

Could corticosteroids increase mortality in COVID-19 patients without high oxygen supplementation?

Nanopore technology allows point-of-care SARS-CoV-2 genomic sequencing

Vaccine hesitancy among young adults may stall efforts to achieve herd immunity

COVID-19 vaccine booster strategy against Delta variant evidence of growing inequity, says WHO

Is niclosamide a potential SARS-CoV-2 antiviral inhibitor?

Researchers examine efficacy of CT-P59 monoclonal antibody against SARS-CoV-2 Brazil variant

SARS-CoV-2 variants show distinct humoral response and transcriptional profiles in hamster model

High individual-level variability in SARS-CoV-2 shedding may explain superspreading

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Israeli study of breakthrough infections following full BNT-Pfizer vaccination, 40% immunocompromised

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News